从三道″连环关卡″看生物制剂规模化的系统性困局
引言:一个共识之后,更难的问题才刚开始
"创新不缺,规模难成。"
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate
Regenxbio (NASDAQ: RGNX) shares nosedived 43% over two days late last week, reaching 52-week lows on consecutive days, despite generating positive pivotal Phase III data for its Duchenne muscular dystrophy (DMD) gene therapy candidate RGX-202.
South Korea’s Soyft Biome Bags Funding to Upcycle Tempeh Waste Into Plant-Based Dairy
Turning plant-based waste into non-dairy products, South Korea’s Soyft Biome is looking to take its climate-friendly alternatives to more coffee shops and bakeries across the country.
Tate & Lyle and Ingredion discuss takeover amid personal care push
British ingredient supplier Tate & Lyle has confirmed that it is in talks with its US rival, Ingredion, over a potential takeover valued at £2.74 billion (US$3.7 billion).
Bunge Opens First New US Soy Protein Concentrate Plant in Over Four Decades
Agribusiness giant Bunge has inaugurated a soy protein concentrate facility in Morristown, Indiana, its first such US facility in more than 40 years and now the largest of its kind in the country. The plant is dedicated exclusively to food-grade production and positions Bunge to expand its supply of plant protein ingredients to food manufacturers across North America and beyond.
IFF opens Vanilla Innovation Center to boost sustainable fragrance development
International Flavors and Fragrances (IFF) has opened a Vanilla Innovation Center in Madagascar, which is designed to push the boundaries of fragrance creation, combining science and creativity directly at the source.
Valsoia Enters Plant-Based Kefir with Italy’s First Drinkable Alternative
Italian health food company Valsoia is launching KEF Valsoia, a 100% plant-based drinkable kefir alternative it says is the first of its kind on the Italian market, alongside a new plant-based skyr-style product. Both were previewed at TuttoFood Milano this month.
RAGE Implicated in Worsening Breast Cancer Mortality with Age
Researchers at Georgetown’s Lombardi Comprehensive Cancer Center have identified a mechanism that may help to explain why older people experience worse outcomes from breast cancer. The study in different mouse breast cancer models and in human breast cancers implicates RAGE (receptor for advanced glycation end-products), a cell surface receptor that amplifies inflammatory signaling, and which also becomes increasingly active with metastatic progression. The study findings in addition suggested that inhibiting RAGE may offer a well-tolerated adjunctive breast cancer therapy in older patients.
World Bee Day 2026: Why Bees Matter for Global Food Security and Biodiversity
May 2026, London: Every year on 20 May, the world observes World Bee Day to recognize the role of bees and oth…
Así Fragrances’ debut spotlights luxury scents for layering, experimentation and self-expression
Así Fragrances has hit the market with a collection of over 50 personal and home fragrance products. The range highlights premium luxury-inspired scents starting at US$39.
